Beautiful Virgin Islands

Wednesday, May 13, 2026

"Very Good, Very Quick": UK PM Receives First Dose Of AstraZeneca Vaccine

"Very Good, Very Quick": UK PM Receives First Dose Of AstraZeneca Vaccine

Boris Johnson had spent a week at St Thomas' Hospital, including three days in intensive care, after being diagnosed with Covid at the end of March last year.
British Prime Minister Boris Johnson on Friday received a first dose of AstraZeneca's Covid vaccine, at the London hospital where he fought for his life almost a year ago, assuring the public the jab is safe.

"I literally did not feel a thing. It was very good, very quick," the 56-year-old leader told reporters at St Thomas' Hospital in central London, close to his Downing Street residence.

"Everybody, when you do get your notification to go for a jab, please go and get it," Johnson said.

"It's the best thing for you, the best thing for your family and for everybody else," he added, stressing the renewed green light given by scientists in Europe for the AstraZeneca jab.

"The risk is Covid. This is a great thing to do," Johnson said, hours after French Prime Minister Jean Castex received the AstraZeneca injection live on television.

Johnson spent a week at St Thomas' Hospital, including three days in intensive care, after he was diagnosed with the coronavirus at the end of March last year.

He said after coming out that his personal battle with the coronavirus "could have gone either way", and there was "no question" doctors saved his life.

AstraZeneca's jab, developed with Oxford University, provides the bulk of Britain's inoculation campaign and a large portion of its supply has been produced by the Serum Institute of India, the world's biggest vaccine maker.

The institute this week said it could not provide planned deliveries next month, denting Britain's otherwise impressive campaign, which has delivered more than 26 million first doses.

The supply issues are another headache for AstraZeneca after its jab was suspended in several EU countries, pending a review by the European Medicines Agency following isolated cases of blood clots and brain haemorrhages.

The EMA restated its approval for the vaccine on Thursday, as did Britain's own drugs regulator.
Newsletter

Related Articles

Beautiful Virgin Islands
0:00
0:00
Close
The Great Western Exit: Why Best Citizens Are Fleeing the Rich World [PODCAST]
The New Robber Barons of Intelligence: Are AI Bosses More Powerful Than Rockefeller?
The End of the Old Order [Podcast]
Britain’s Democracy Is Now a Costume
The AI Gold Rush Is Coming for America’s Last Open Spaces [Podcast]
The Pentagon’s AI Squeeze: Eight Tech Giants Get In, Anthropic Gets Shut Out [Podcast]
The War Map: Professor Jiang’s Dark Theory of Iran, Trump, China, Russia, Israel, and the Coming Global Shock [Podcast]
Labour Is No Longer a National Party [Podcast]
AI Isn’t Stealing Your Job. It’s Dismantling It Piece by Piece.
Lawyers vs Engineers: Why China Builds While America Litigates [Podcast]
Churchill’s Glass: The Drunk, the Doctor, and the Myth Britain Refuses to Sober Up From
Apple issues an unusual warning: this is how your iPhone can be hacked without you doing anything
The Met Gala Meets the Age of Billionaire Backlash
Russian Oligarch’s Superyacht Crosses Hormuz via Iran-Controlled Route
Gunfire Disrupts White House Correspondents’ Dinner as Trump Is Evacuated
A Leak, a King, and a Fracturing Alliance
Inside the Gates Foundation Turmoil: Layoffs, Scrutiny, and the Cost of Reputational Risk
UK Biobank Breach Exposes Health Data of 500,000, Listed for Sale on Chinese Platform
KPMG Cuts Around 10% of US Audit Partners After Failed Exit Push
French Police Probe Suspected Weather-Data Tampering After Unusual Polymarket Bets on Paris Temperatures
News Roundup
Microsoft lost 2.5 millions users (French government) to Linux
Privacy Problems in Microsoft Windows OS
News roundup
Péter András Magyar and the Strategic Reset of Hungary
Hungary After the Landslide — A Strategic Reset in Europe
×